Abstract
BackgroundUpadacitinib (UPA) is an oral, JAK1-selective inhibitor found to be effective in Phase 2 and 3 studies in rheumatoid arthritis (RA) patients with inadequate response or intolerance to csDMARDs and...
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have